Recent Quotes View Full List My Watchlist Create Watchlist Indicators DJI Nasdaq Composite SPX Gold Crude Oil EL&P Market Index Markets Stocks ETFs Tools Overview News Currencies International Treasuries Supernus Pharm (NQ: SUPN ) 32.22 +0.33 (+1.03%) Streaming Delayed Price Updated: 10:18 AM EDT, Oct 11, 2024 Add to My Watchlist Quote Overview Detailed Quote Charting Historical Prices News All News News Headlines Press Releases Research Quarterly Reports Insider Filings Other Filings Price and Volume Detailed Quote Volume 21,584 Open 32.17 Bid (Size) 32.21 (3) Ask (Size) 32.34 (18) Prev. Close 31.89 Today's Range 31.99 - 32.30 52wk Range 21.99 - 35.44 Shares Outstanding 53,145,884 Dividend Yield N/A Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year Top News More News Supernus Pharmaceuticals to Host Webcast to Review Open-Label Phase 2a Study of SPN-820 for the Treatment of Major Depressive Disorder October 10, 2024 From Supernus Pharmaceuticals, Inc. Via GlobeNewswire Busy Philipps Encourages Women to Take Charge of Their ADHD This Fall in Ongoing Collaboration with Supernus Pharmaceuticals and Qelbree September 24, 2024 From Supernus Pharmaceuticals, Inc. Via GlobeNewswire Performance YTD +16.19% +16.19% 1 Month -3.79% -3.79% 3 Month +13.09% +13.09% 6 Month +0.69% +0.69% 1 Year +19.07% +19.07% More News Read More Supernus Pharmaceuticals to Participate in the TD Cowen 4th Annual Novel Mechanisms in Neuropsychiatry Summit September 19, 2024 From Supernus Pharmaceuticals, Inc. Via GlobeNewswire ADHD Drug Maker Supernus Pharmaceuticals Downgraded On Slower Prescription Growth For Its Top-Selling Drug September 11, 2024 Via Benzinga This Novartis Analyst Is No Longer Bullish; Here Are Top Downgrades For Wednesday September 11, 2024 Via Benzinga Domino's Pizza To $510? Here Are 10 Top Analyst Forecasts For Wednesday September 11, 2024 Via Benzinga Supernus Pharmaceuticals to Participate in the 2024 Wells Fargo Healthcare Conference August 28, 2024 From Supernus Pharmaceuticals, Inc. Via GlobeNewswire Supernus Announces SPN-830 Apomorphine Infusion Device NDA Accepted for Review by FDA August 19, 2024 From Supernus Pharmaceuticals, Inc. Via GlobeNewswire Supernus Announces Second Quarter 2024 Financial Results August 06, 2024 From Supernus Pharmaceuticals, Inc. Via GlobeNewswire For those who appreciate value investing, NASDAQ:SUPN is a compelling option with its solid fundamentals. August 06, 2024 Via Chartmill Supernus Resubmits NDA for SPN-830 Apomorphine Infusion Device August 01, 2024 From Supernus Pharmaceuticals, Inc. Via GlobeNewswire Supernus Pharmaceuticals to Announce Second Quarter 2024 Financial Results and Host Conference Call on August 6, 2024 July 23, 2024 From Supernus Pharmaceuticals, Inc. Via GlobeNewswire If You Can Only Buy One Biotech Stock in July, It Better Be One of These 3 Names July 19, 2024 Via InvestorPlace NASDAQ:SUPN is a prime example of a stock that offers more than what meets the eye in terms of fundamentals. July 05, 2024 Via Chartmill Trading SMID Biotech Stocks In A Volatile Market July 01, 2024 Via Talk Markets Investors should take notice of NASDAQ:SUPN—it offers a great deal for the fundamentals it presents. June 14, 2024 Via Chartmill Supernus Pharmaceuticals to Participate in the Jefferies Global Healthcare Conference May 30, 2024 From Supernus Pharmaceuticals, Inc. Via GlobeNewswire Supernus Announces Promising Interim Data from Ongoing Open-Label Phase 2a Study of SPN-817 in Epilepsy May 23, 2024 From Supernus Pharmaceuticals, Inc. Via GlobeNewswire Supernus Pharmaceuticals to Host Webcast to Review Interim Data from Ongoing Open-Label Phase IIa Study of SPN-817 for Treatment-Resistant Seizures May 09, 2024 From Supernus Pharmaceuticals, Inc. Via GlobeNewswire SUPN Stock Earnings: Supernus Pharmaceuticals Misses Revenue for Q1 2024 May 08, 2024 Via InvestorPlace Supernus Announces First Quarter 2024 Financial Results May 08, 2024 From Supernus Pharmaceuticals, Inc. Via GlobeNewswire Glancy Prongay & Murray LLP, a Leading Securities Fraud Law Firm, Announces Investigation of Supernus Pharmaceuticals, Inc. (SUPN) on Behalf of Investors May 02, 2024 From Glancy Prongay & Murray LLP Via Business Wire INVESTOR ALERT: Law Offices of Howard G. Smith Announces Investigation of Supernus Pharmaceuticals, Inc. (SUPN) on Behalf of Investors May 01, 2024 From Law Offices of Howard G. Smith Via Business Wire Busy Philipps Shines Spotlight on ADHD in Women and Shares her Qelbree Story May 01, 2024 From Supernus Pharmaceuticals, Inc. Via GlobeNewswire The Law Offices of Frank R. Cruz Announces Investigation of Supernus Pharmaceuticals, Inc. (SUPN) on Behalf of Investors April 29, 2024 From The Law Offices of Frank R. Cruz Via Business Wire Data & News supplied by www.cloudquote.io Stock quotes supplied by Barchart Quotes delayed at least 20 minutes. By accessing this page, you agree to the following Privacy Policy and Terms and Conditions.
